CRISPR Therapeutics AG (NASDAQ:CRSP) ranks among the best biotech stocks to buy. Following CRISPR Therapeutics AG (NASDAQ:CRSP)’s collaboration with Sirius on FXI siRNA SRSD107, BMO Capital reaffirmed its Outperform rating and $75 price target on the company’s shares on September 23. The collaboration has resulted in the start of a Phase II trial for the prevention of venous thromboembolism (VTE), which does not include gene editing. Clinical evidence from studies on atrial fibrillation (AF) and total kn ...

Core Insights - CRISPR Therapeutics is focused on creating transformative gene-based medicines for serious diseases [3] - The company has made progress with its therapy CASGEVY, which is being commercialized in partnership with Vertex [4] - Several clinical trials are ongoing, with readouts expected in the next 6 to 12 months that will influence the company's strategic direction [4] - The company has multiple preclinical programs and aims to expand its pipeline significantly over the long term [5] Company Overview - Raju Prasad, the Chief Financial Officer, provided an overview of the company's goals and current projects [2] - The company is leveraging its gene-editing technology to develop additional products beyond CASGEVY [4] - Resource allocation is a consideration for the company as it seeks to grow its offerings sustainably [5]

Cellectis Today CLLS Cellectis $1.38 -0.07 (-4.83%) 52-Week Range $1.10 ▼ $3.38 Price Target $7.00 Add to Watchlist Cellectis S.A. NASDAQ: CLLS is a clinical-stage biotechnology company focused on developing 'off-the-shelf' cancer immunotherapies using gene-editing technology. Following a substantial strategic equity investment from AstraZeneca NASDAQ: AZN and a strengthened financial position reported in its full-year 2024 results, Cellectis has entered a potentially pivotal stage in its market narrative. ...